Tinavi Medical vs Globus Medical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Tinavi Medical Technologies Co Ltd (688277.CG)

Q3 202615 Jul – 29 Jul 2026

▲2

Tinavi to buy 62% of Shanghai Orthopedics, adding implants to robot business

Tinavi to acquire 62% of Shanghai Orthopedics via share issuance Tinavi will buy a 62% controlling stake in Shanghai Minimally Invasive Orthopedics, a maker of joint implants, using newly issued shares. This fills the missing implant part of its product line, letting it sell robots plus implants together. The stock resumes trading July 30.
This is the core new event that directly changes Tinavi's business and drives the stock.
Deal creates robot-plus-implant synergy and long-term growth potential Combining Tinavi's surgical robots with Shanghai Orthopedics' hip and knee implants should boost sales through shared hospitals and doctors, and speed up new product development. The target's knee implant has a strong 17-year survival rate and sells in the US, Japan and Europe.
Explains why the acquisition could lift future earnings, not just headline news.
Deal is still subject to approvals and due diligence The acquisition is a major restructuring and needs regulatory approvals, due diligence and a formal agreement. It could still fall through. Also, paying with new shares dilutes existing shareholders, though the company says control will not change.
Provides the real counterweight: execution risk and share dilution could cap gains.

July 202615 Jul – 29 Jul 2026

▲2

Tinavi to buy 62% of Shanghai Orthopedics, adding implants to robot business

Tinavi to acquire 62% of Shanghai Orthopedics via share issuance Tinavi will buy a 62% controlling stake in Shanghai Minimally Invasive Orthopedics, a maker of joint implants, using newly issued shares. This fills the missing implant part of its product line, letting it sell robots plus implants together. The stock resumes trading July 30.
This is the core new event that directly changes Tinavi's business and drives the stock.
Deal creates robot-plus-implant synergy and long-term growth potential Combining Tinavi's surgical robots with Shanghai Orthopedics' hip and knee implants should boost sales through shared hospitals and doctors, and speed up new product development. The target's knee implant has a strong 17-year survival rate and sells in the US, Japan and Europe.
Explains why the acquisition could lift future earnings, not just headline news.
Deal is still subject to approvals and due diligence The acquisition is a major restructuring and needs regulatory approvals, due diligence and a formal agreement. It could still fall through. Also, paying with new shares dilutes existing shareholders, though the company says control will not change.
Provides the real counterweight: execution risk and share dilution could cap gains.

Latest15 Jul – 29 Jul 2026

▲2

Tinavi to buy 62% of Shanghai Orthopedics, adding implants to robot business

Tinavi to acquire 62% of Shanghai Orthopedics via share issuance Tinavi will buy a 62% controlling stake in Shanghai Minimally Invasive Orthopedics, a maker of joint implants, using newly issued shares. This fills the missing implant part of its product line, letting it sell robots plus implants together. The stock resumes trading July 30.
This is the core new event that directly changes Tinavi's business and drives the stock.
Deal creates robot-plus-implant synergy and long-term growth potential Combining Tinavi's surgical robots with Shanghai Orthopedics' hip and knee implants should boost sales through shared hospitals and doctors, and speed up new product development. The target's knee implant has a strong 17-year survival rate and sells in the US, Japan and Europe.
Explains why the acquisition could lift future earnings, not just headline news.
Deal is still subject to approvals and due diligence The acquisition is a major restructuring and needs regulatory approvals, due diligence and a formal agreement. It could still fall through. Also, paying with new shares dilutes existing shareholders, though the company says control will not change.
Provides the real counterweight: execution risk and share dilution could cap gains.

Globus Medical (GMED)

Q3 202617 Jul – 24 Sep 2026

▲3▼1

Globus Medical beats Q2, buys AI health firm, wins EU clearance for imaging robot

Q2 beat and raised guidance Globus Medical reported Q2 revenue of $789.6 million, up 5.9% and above estimates, and beat profit expectations while raising full-year guidance. US Spine rose 7% and international spine 14%, showing the core business is still taking market share.
The latest earnings beat and guidance raise are the clearest new evidence of business strength.
AI digital health acquisition Globus Medical bought Higgs Boson Health, a Duke-incubated AI software company, to build 'surgical intelligence' that tracks patient outcomes across the whole episode of care. It adds technology and talent rather than near-term sales, so it supports the long-term growth story more than this quarter's numbers.
A new acquisition expands Globus Medical's technology and talent, a fresh strategic driver.
EU approval for Excelsius3D imaging system Globus Medical's Excelsius3D imaging system received CE marking, letting it be sold in the EU and UK. The system combines 3D CT, 2D fluoroscopy and digital X-ray and works with its ExcelsiusGPS surgical robot, so it can lift sales of the whole robotic ecosystem abroad.
New regulatory clearance opens European commercialization, a concrete new growth avenue.
Insurance worries and governance probe Intuitive Surgical warned that insurance plan changes could slow US procedure growth, dragging medical device stocks including Globus Medical down 4.4%. Separately, Kuehn Law is investigating whether Globus Medical officers and directors breached their duties through possible self-dealing, a governance cloud that can weigh on sentiment.
These are the main new negatives: a sector demand scare and a legal/governance investigation.

August 202617 Jul – 24 Sep 2026

▲3▼1

Globus Medical beats Q2, buys AI health firm, wins EU clearance for imaging robot

Q2 beat and raised guidance Globus Medical reported Q2 revenue of $789.6 million, up 5.9% and above estimates, and beat profit expectations while raising full-year guidance. US Spine rose 7% and international spine 14%, showing the core business is still taking market share.
The latest earnings beat and guidance raise are the clearest new evidence of business strength.
AI digital health acquisition Globus Medical bought Higgs Boson Health, a Duke-incubated AI software company, to build 'surgical intelligence' that tracks patient outcomes across the whole episode of care. It adds technology and talent rather than near-term sales, so it supports the long-term growth story more than this quarter's numbers.
A new acquisition expands Globus Medical's technology and talent, a fresh strategic driver.
EU approval for Excelsius3D imaging system Globus Medical's Excelsius3D imaging system received CE marking, letting it be sold in the EU and UK. The system combines 3D CT, 2D fluoroscopy and digital X-ray and works with its ExcelsiusGPS surgical robot, so it can lift sales of the whole robotic ecosystem abroad.
New regulatory clearance opens European commercialization, a concrete new growth avenue.
Insurance worries and governance probe Intuitive Surgical warned that insurance plan changes could slow US procedure growth, dragging medical device stocks including Globus Medical down 4.4%. Separately, Kuehn Law is investigating whether Globus Medical officers and directors breached their duties through possible self-dealing, a governance cloud that can weigh on sentiment.
These are the main new negatives: a sector demand scare and a legal/governance investigation.

Latest17 Jul – 24 Sep 2026

▲3▼1

Globus Medical beats Q2, buys AI health firm, wins EU clearance for imaging robot

Q2 beat and raised guidance Globus Medical reported Q2 revenue of $789.6 million, up 5.9% and above estimates, and beat profit expectations while raising full-year guidance. US Spine rose 7% and international spine 14%, showing the core business is still taking market share.
The latest earnings beat and guidance raise are the clearest new evidence of business strength.
AI digital health acquisition Globus Medical bought Higgs Boson Health, a Duke-incubated AI software company, to build 'surgical intelligence' that tracks patient outcomes across the whole episode of care. It adds technology and talent rather than near-term sales, so it supports the long-term growth story more than this quarter's numbers.
A new acquisition expands Globus Medical's technology and talent, a fresh strategic driver.
EU approval for Excelsius3D imaging system Globus Medical's Excelsius3D imaging system received CE marking, letting it be sold in the EU and UK. The system combines 3D CT, 2D fluoroscopy and digital X-ray and works with its ExcelsiusGPS surgical robot, so it can lift sales of the whole robotic ecosystem abroad.
New regulatory clearance opens European commercialization, a concrete new growth avenue.
Insurance worries and governance probe Intuitive Surgical warned that insurance plan changes could slow US procedure growth, dragging medical device stocks including Globus Medical down 4.4%. Separately, Kuehn Law is investigating whether Globus Medical officers and directors breached their duties through possible self-dealing, a governance cloud that can weigh on sentiment.
These are the main new negatives: a sector demand scare and a legal/governance investigation.